About IDEAYA Biosciences Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.ideayabio.com/
Frequently Asked Questions
What is the 52-week range for IDYA?
The 52-week high is $42.68 and the 52-week low is $26.05.
What is the P/E ratio for IDYA?
The P/E ratio data is currently unavailable.
What is the dividend yield for IDYA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -16.47%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -74.75%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.96.
Analyst Recommendation Trends
Wall Street analyst consensus for IDYA over the last few months:
Latest IDYA News
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced the promotion of Dr. Michael White, from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.
Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts
On August 11, Sagimet Biosciences Inc. (NASDAQ:SGMT) reported financial results for the quarter ended June 30, 2026. Research and development expense rose to $11.5 million from $7.2 million a year earlier as the company prepared for its Phase 3 trial, while general and administrative expense declined slightly to $4.3 million. Net loss widened to $14.0 […]
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on September 24, 2026, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 94,000 shares of the Company's common stock to three newly hired employees. The stock options were granted under the IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award
Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold?
Pre-commercial precision oncology firms often face steep financial trade-offs, where absent return on invested capital/ROIC and negative operating cash flows are the price of admission for long-term clinical innovation. IDEAYA Biosciences (NASDAQ:IDYA) operates from a position of relative balance sheet strength, backed by $1.24 billion in cash, cash equivalents, and marketable securities that extend its […]
IDEAYA Biosciences, Inc. (IDYA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
IDEAYA Biosciences, Inc. (IDYA) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 7:00 AM EDTCompany ParticipantsYujiro Hata -...
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Servier, an independent international pharmaceutical group governed by a foundation, today announced that the first patient has been dosed in OptimUM-11, a global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C (PKC) inhibitor, in combination with crizotinib, an oral cMET inhibitor, as adjuvant therapy for patients with primary uveal melanoma who have completed
Guggenheim Maintains Buy on IDEAYA Biosciences, Raises Price Target to $57
Guggenheim analyst Paul Jeng maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Buy and raises the price target from $54 to $57.
IDEAYA Biosciences Announced First Patient Has Been Dosed In The OptimUM-11 Phase 3 Registrational Trial Evaluating Darovasertib In Combination With Crizotinib For Patients With Primary Uveal Melanoma
Global Phase 3 registrational trial evaluating darovasertib, a first-in-class oral protein kinase C (PKC) inhibitor, in combination with crizotinib, an oral cMET inhibitor, as adjuvant therapy for patients with primary
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-07 | Ruiz Briseno Andres | -9,550 | - | - |
| 2026-07-07 | Ruiz Briseno Andres | -9,550 | $40.0137 | $382,131 |
| 2026-07-07 | Ruiz Briseno Andres | +9,550 | $12.86 | $122,813 |
| 2026-06-16 | MACKEY CATHERINE J | +20,000 | - | - |
| 2026-06-16 | Stein Jeffrey | +20,000 | - | - |
| 2026-06-16 | ROSEN TERRY J | +20,000 | - | - |
| 2026-06-16 | YARNO WENDY L | +20,000 | - | - |
| 2026-03-02 | Stein Jeffrey | +50,000 | $32.9578 | $1,647,890 |
| 2026-01-30 | Bleharski Joshua | +170,000 | - | - |
| 2026-01-30 | WHITE MICHAEL ANTHONY | +190,000 | - | - |
| 2026-01-30 | DORMAN STUART | +155,000 | - | - |
| 2026-01-30 | Snyder Douglas B. | +130,000 | - | - |
| 2026-01-30 | Ruiz Briseno Andres | +80,000 | - | - |
| 2026-01-30 | Hata Yujiro S | +600,000 | - | - |
| 2026-01-30 | Beaupre Darrin | +175,000 | - | - |
| 2025-11-28 | Snyder Douglas B. | +1,041 | $16.9065 | $17,600 |
| 2025-11-28 | Ruiz Briseno Andres | +1,253 | $16.9065 | $21,184 |